Assessment of cardiovascular functions in children with attention-deficit/hyperactivity disorder who are new users of methylphenidate

Basit Öğe Kaydı
dc.contributor.authorSargin, Fatma
dc.contributor.authorOflaz, Mehmet Burhan
dc.contributor.authorYar, Ahmet
dc.contributor.authorBaysal, Tamer
dc.date.accessioned2024-02-23T14:49:18Z
dc.date.available2024-02-23T14:49:18Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjectives: It was aimed to evaluate cardiovascular functions via blood pressure and electrocardiogram (ECG) of patients with attention deficit and hyperactivity disorder (ADHD) who were treated with methylphenidate. Design: This is a descriptive and prospective study. Settings: Necmettin Erbakan University Meram Faculty of Medicine and Konya Training and Research Hospital, Turkey Subjects: Thirty-five patients with ADHD who were selected to be treated with methylphenidate were evaluated using ECG, heart rate (beats/minute), systolic blood pressure (mmHg) and diastolic blood pressure (mmHg) recorded before treatment, and after 1st month and 3rd month of treatment. Interventions: Heart rate, rhythm, QRS axis, P-R interval, P dispersion, QT dispersion, QTc interval and QTc dispersion were measured on ECG. Main outcome measures: ECG changes of patients with ADHD who were treated with methylphenidate Results: There were no statistically significant differences in the heart rate, systolic blood pressure, diastolic blood pressure, P-R interval, P dispersion, QT dispersion and QTc dispersion between the measurements performed at baseline and at one and three months of treatment. Statistically significantly increased QRS axes were observed at baseline, and at one and three months of treatment, although this increase was not clinically significant. None of the patients had adverse cardiovascular events. Conclusion: In conclusion, methylphenidate which is used commonly in the treatment of ADHD does not alter the heart rate, blood pressure and ECG recordings at one and three months of treatment compared to the baseline.en_US
dc.identifier.endpage255en_US
dc.identifier.issn0023-5776
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85090661368en_US
dc.identifier.startpage250en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/18114
dc.identifier.volume52en_US
dc.identifier.wosWOS:000590422500005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKuwait Medical Assocen_US
dc.relation.ispartofKuwait Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAttention-Deficit/Hyperactivity Disorderen_US
dc.subjectElectrocardiographyen_US
dc.subjectMethylphenidateen_US
dc.titleAssessment of cardiovascular functions in children with attention-deficit/hyperactivity disorder who are new users of methylphenidateen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu